Erythropoietin can deteriorate glucose control in uraemic non-insulin- dependent diabetic patients

Diabetes and Metabolism

Volumn 24, Issue 1, 1998, Pages 62-65

  Rigalleau, V ^a   Blanchetier, V ^b   Aparicio, M ^b   Baillet, L ^a   Sneed, J ^b   Dabadie, H ^a   Gin, H ^a  

^a Service de Diabétologie Nutrition   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

Chronic renal failure; Erythropoietin; Insulin; Non insulin dependent diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; EPISTAXIS; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; SUBCUTANEOUS DRUG ADMINISTRATION; UREMIA;

AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; UREMIA;

EID: 0031932167     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Eschbach JW. The anemia of chronic renal failure : pathophysiology and the effects of recombinant erythropoietin. Kidney Int., 1989, 35, 134-148.
2. Onoyama K, Kumagai H, Tadeka K, Shimatsu K, Fujishima M. Effects of recombinant human erythropoietin on anemia, systemic haeniodynamics, and renal function in preanalysis renal failure patients. Nephrol Dial Transplant, 1989, 4, 966-970.
3. Cordonnier DJ, Zmirou D, Benhamou PY, Halimi S, Ledoux F, Guiserix J. Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1993, 36, 1109-1112.
4. Borissova AM, Jambazova M, Todorov K, Dakovska L, Tankova T, Kirilov G. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on hemodialysis. Nephrol Dial Transplant, 1993, 8, 93.
5. Allegra V, Mengozzi G, Martimbianco L, Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol, 1996, 16, 304-308.
6. Chagnac A, Wenstein T, Zevin D, et al. Effect of erythropoietin on glucose tolerance in hemodialysis patients. Clin Nephrol, 1994, 42, 398-400.
7. Kokot T, Nieszporek T, Wiecek A, Marcinkowski W, Rudka R, Trembecki J. Influence of long-term erythropoietin treatment on insulin, glucagon, pancreatic polypeptide, and gastrin secretion in haemodialized patients. Nephrol Dial Transplant, 1994, suppl 3, 35-39.
8. Eidemak I, Feldt-Rasmussen B, Kanstrup IL, Nielsen SL, Schmilz O, Strandgaard S. Insulin resistance and hyperinsulinemia in mild to moderate progressive renal failure and its association with aerobic work capacity. Diabetoiogia, 1995, 38, 565-572.
9. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J, 1990, 300, 573-578.
10. Davenport A, Kiung RFGJ, Ironside JW, Will EJ, Davison AM. The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital haemodialysis. Nephron, 1993, 64, 89-94.
11. Moan A, Nordby G, Os I, Birkeland KI, Kjeldsen SE. Relationship between hemorrheologic factors and insulin sensitivity in healthy young men. Metabolism, 1994, 43, 423-427.
12. Ferrannini E, Buzzigioli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med, 1987, 317, 350-357.
13. Jandeleit K, Heintz B, Gross-Heitfeld E, et al. Increased activity of the autonomie nervous system and increased sensitivity to angiotensin II after therapy with recombinant human erythropoietin. Nephron, 1990, 56, 220-221.
14. Akpolat T, Arik N, Demirkan F, et al. Acute effect of erythropoietin on catecholamine levels in uremia. Nephron, 1993, 64, 329-330.